Explore this article's sources with AI
Follow PeptideMethods on Google
CJC-1295 Dosing in Human Studies
Human CJC-1295 studies report dose levels for short hormone-response experiments, not an approved dose or a self-use protocol.
Why we wrote this. Trial dose figures are often copied as instructions. This reports their study context without turning them into a protocol.
In this article (5 sections)
The human literature on CJC-1295 reports a few dose levels from short, early studies in healthy adults. It does not establish a therapeutic dose or a self-use schedule. Nor does it establish dosing for bodybuilding, recovery or sleep, much less longevity. The main publication combined two placebo-controlled ascending-dose trials. A second paper studied one administration in healthy men. Both measured growth hormone and insulin-like growth factor 1 (IGF-1), not clinical benefit[1][2].
This article reports what those studies administered and why. It is not a dosing protocol. The studied molecule was the long-acting albumin-binding form developed as CJC-1295, often called the with-DAC form in later marketing. Results from that material should not be assumed to apply to products sold as CJC-1295 without DAC.
The first human programme used ascending doses
Teichman and colleagues published the central human paper in 2006. It combined two randomized, placebo-controlled, double-blind ascending-dose trials with durations of 28 and 49 days. Participants were healthy adults aged 21 to 61. In the first trial, CJC-1295 or placebo was given as one of four ascending single doses. In the second, participants received two or three administrations on weekly or every-two-week schedules[1]. The abstract does not enumerate every group, so a summary should not invent a complete dose table from that record.
The authors' conclusion specifically highlights 30 and 60 micrograms per kilogram as doses at which the compound was relatively well tolerated. After one administration, mean GH rose by twofold to tenfold for at least six days, while mean IGF-1 rose by 1.5-fold to threefold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days. After repeated administrations, mean IGF-1 remained above baseline for as long as 28 days[1]. No serious adverse reactions were reported in these short trials.
Why did the investigators use an ascending design? Early dose-escalation studies look for exposure and biological response before later efficacy work. They also record immediate tolerability. They are not designed to identify an optimal dose for a disease. Here, the outcomes were hormone concentrations and pharmacokinetic measures. The participants were not enrolled for injury treatment or fat loss, and the trial did not study anti-aging care.
The pulsatility study used 60 or 90 micrograms per kilogram
Ionescu and Frohman asked a narrower physiology question: would prolonged GHRH-receptor stimulation erase the pituitary gland's pulsatile pattern of GH secretion? Healthy men aged 20 to 40 underwent overnight blood sampling before and one week after one 60 or 90 microgram-per-kilogram CJC-1295 administration[2]. Those dose levels were selected to study hormone dynamics, not to compare therapeutic outcomes.
The frequency and size of GH pulses were unchanged. Trough GH rose 7.5-fold, mean GH rose 46%, and IGF-1 rose 45%. The paper also reported no significant difference in response between the two dose groups[2]. This finding is sometimes shortened to 'CJC-1295 preserves natural pulses.' That leaves out the raised GH level between pulses and the fact that the experiment observed participants for a physiology endpoint one week after a single administration.
What the dose figures can and cannot show
A dose used in a trial answers what exposure produced the reported measurements under that protocol. It does not become a recommendation when copied into a forum. The 30, 60, and 90 microgram-per-kilogram figures came from small studies of defined investigational material, screened participants, and scheduled measurements. They do not validate a fixed microgram amount sold online, and they do not account for an individual's health conditions or medicines.
The foundational development paper also makes the formulation boundary clear. ConjuChem researchers designed CJC-1295 with a reactive group that binds the peptide to serum albumin. In rats, the selected compound remained detectable beyond 72 hours and produced more GH exposure than unmodified hGRF(1-29)[3]. That albumin-binding design is the reason the later human studies measured a multi-day half-life. Removing the linker creates a different molecule and removes the basis for treating the published schedule as interchangeable.
A 2026 sports-medicine review reached the same practical boundary from a broader angle. It found that CJC-1295 plus ipamorelin had animal rather than human combination evidence and concluded that indications, dosing, frequency, and duration remained unknown for the popular injectable peptide approaches reviewed[4]. There is no controlled human trial that turns the CJC-1295 hormone-response papers into a regimen for a CJC-1295 and ipamorelin blend.
Why body weight conversions still are not instructions
The historical papers reported micrograms per kilogram, which is a weight-normalized research unit. Multiplying one of those figures by a person's body weight would only reproduce the arithmetic of a study group. It would not show that the resulting amount is appropriate, safe, or effective for that person. It would also ignore formulation identity. For those reasons, this article does not provide worked personal-dose conversions or syringe calculations.
Readers comparing the two molecules can use our CJC-1295 with DAC versus without DAC explainer. The CJC-1295 reference page covers the mechanism, evidence level, and country links. Neither page recommends a vendor or a protocol.
What we do not yet know
The published human studies do not establish a therapeutic dose for any indication. They do not compare long-term schedules, define a dose-response relationship for clinical benefit, or evaluate months and years of exposure. They also do not establish dosing for the without-DAC molecule or for any combination with ipamorelin. Short early-phase tolerability cannot exclude uncommon or delayed harms.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
What CJC-1295 doses were used in human studies?
The main 2006 paper used ascending single and repeated doses and highlights 30 and 60 micrograms per kilogram in its abstract. A separate pulsatility study used one 60 or 90 microgram-per-kilogram administration. These are historical trial exposures, not recommendations.
Did the studies identify an optimal CJC-1295 dose?
No. The studies measured pharmacokinetics and changes in GH and IGF-1 in healthy adults. They did not test clinical benefit for a disease and did not establish an optimal or approved dose.
Do the trial doses apply to CJC-1295 without DAC?
No direct human evidence establishes that. The studied CJC-1295 used an albumin-binding design that produced a multi-day half-life. The molecule sold as CJC-1295 without DAC lacks that linker and should not be assumed to share the same pharmacokinetics or schedule.
Have CJC-1295 and ipamorelin been dosed together in a human trial?
No controlled human trial has established a dose or schedule for that named combination. A 2026 review found animal combination evidence and stated that dosing, frequency, and duration remained unknown.
Sources
- [1]Teichman et al. (2006): Prolonged GH and IGF-I stimulation by CJC-1295 in healthy adults (PMID 16352683)Tier 1 · primary↩
- [2]Ionescu and Frohman (2006): GH pulsatility during continuous stimulation by CJC-1295 (PMID 17018654)Tier 1 · primary↩
- [3]Jette et al. (2005): Identification of CJC-1295 as a long-lasting GRF analogue (PMID 15817669)Tier 1 · primary↩
- [4]Mayfield et al. (2026): Injectable peptide therapy primer for orthopaedic and sports medicine physicians (PMID 41476424)Tier 1 · primary↩
No revisions yet. First published .